{"id":4556,"date":"2026-07-31T07:16:34","date_gmt":"2026-07-31T07:16:34","guid":{"rendered":"https:\/\/peptoscience.com\/?post_type=product&#038;p=4556"},"modified":"2026-07-31T07:16:44","modified_gmt":"2026-07-31T07:16:44","slug":"saxenda-liraglutide","status":"publish","type":"product","link":"https:\/\/peptoscience.com\/es\/product\/saxenda-liraglutide\/","title":{"rendered":"Saxenda Liraglutide"},"content":{"rendered":"<h1><a href=\"http:\/\/google.com\">Saxenda Liraglutide<\/a><\/h1>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><a href=\"https:\/\/trusthillpharmacy.de\/\">Saxenda<\/a> is a brand-name prescription medication containing\u00a0<strong>liraglutide<\/strong>\u00a0(3 mg\/3 mL solution for subcutaneous injection). It&#8217;s a GLP-1 receptor agonist (glucagon-like peptide-1), mimicking a hormone that regulates appetite and blood sugar. Developed by Novo Nordisk, it&#8217;s FDA-approved\u00a0<strong>specifically for chronic weight management<\/strong>\u00a0in adults and children aged 12+ with obesity or overweight conditions with related health issues (e.g., hypertension, type 2 diabetes, dyslipidemia).<\/p>\n<p class=\"mb-2 last:mb-0\"><strong>Key Uses (FDA-Approved Indications):<\/strong><\/p>\n<ul>\n<li>Weight loss and maintenance in combination with a reduced-calorie diet and increased physical activity.<\/li>\n<li>Not for cosmetic weight loss; requires BMI \u226530 (obese) or \u226527 (overweight) with comorbidities.<br \/>\n<em>(Note: The same drug, liraglutide at a lower dose [1.2\u20131.8 mg], is sold as\u00a0<strong>Victoza<\/strong>\u00a0for type 2 diabetes management.)<\/em><\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>How It Works:<\/strong><\/p>\n<ul>\n<li><strong>Appetite suppression<\/strong>: Slows gastric emptying, increases satiety signals in the brain.<\/li>\n<li><strong>Blood sugar control<\/strong>: Stimulates insulin release, reduces glucagon (evidence from clinical trials like SCALE Obesity and Prediabetes).<\/li>\n<li>Average weight loss: 5\u201310% of body weight over 56 weeks (per STEP trials meta-analysis in\u00a0<em>NEJM<\/em>, 2021).<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Dosage &amp; Administration:<\/strong><\/p>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Week<\/th>\n<th>Dose (subcutaneous injection, once daily)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>0.6 mg<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>1.2 mg<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>1.8 mg<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>2.4 mg<\/td>\n<\/tr>\n<tr>\n<td>5+<\/td>\n<td>3.0 mg (maintenance)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li>Use pre-filled pen; inject into abdomen, thigh, or upper arm.<\/li>\n<li>Max dose: 3 mg\/day. Taper if discontinuing to avoid rebound.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Evidence of Effectiveness:<\/strong><\/p>\n<ul>\n<li><strong>SCALE trials<\/strong>\u00a0(phase 3, &gt;4,800 patients): 63\u201364% achieved \u22655% weight loss vs. 27\u201340% placebo (<em>Lancet<\/em>, 2015).<\/li>\n<li>Sustained results with lifestyle changes; head-to-head vs. semaglutide (Wegovy) shows slightly less efficacy (5\u201315% vs. 15\u201320% loss).<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Common Side Effects (\u22655% incidence):<\/strong><\/p>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Category<\/th>\n<th>Effects<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>GI<\/td>\n<td>Nausea (39%), vomiting (15%), diarrhea (20%), constipation (10%) \u2013 often improve over time.<\/td>\n<\/tr>\n<tr>\n<td>Injection<\/td>\n<td>Redness, itching.<\/td>\n<\/tr>\n<tr>\n<td>Other<\/td>\n<td>Headache (14%), fatigue, low blood sugar (if diabetic).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><strong>Serious Risks (Black Box Warning):<\/strong><\/p>\n<ul>\n<li><strong>Thyroid C-cell tumors<\/strong>: Rodent studies showed risk; human data limited but monitor for symptoms (lump in neck, hoarseness). Contraindicated in personal\/family history of medullary thyroid carcinoma (MTC) or MEN 2.<\/li>\n<li><strong>Pancreatitis<\/strong>: Acute cases reported (0.3%); stop if suspected.<\/li>\n<li><strong>Gallbladder disease<\/strong>: Cholecystitis in 1.5% vs. 0.5% placebo.<\/li>\n<li><strong>Hypoglycemia<\/strong>: Risk with insulin\/sulfonylureas.<\/li>\n<li><strong>Suicidal thoughts<\/strong>: Rare behavioral changes noted.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Contraindications &amp; Warnings:<\/strong><\/p>\n<ul>\n<li>Avoid in: MTC\/MEN 2 history, severe GI disease, pregnancy (Category C; animal fetal harm).<\/li>\n<li>Drug interactions: Slows absorption of oral meds (e.g., birth control, antibiotics).<\/li>\n<li>Cost: ~1,700\/month (US, without insurance); patient assistance programs available.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Monitoring &amp; Lifestyle:<\/strong><\/p>\n<ul>\n<li>Monthly check-ins for first 16 weeks; discontinue if &lt;4% weight loss.<\/li>\n<li>Combine with 500 kcal\/day deficit diet + 150 min\/week exercise for best results (per ADA guidelines).<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Sources:<\/strong>\u00a0FDA label (updated 2023), Novo Nordisk prescribing info,\u00a0<em>JAMA<\/em>\u00a0reviews (2022\u20132024), clinicaltrials.gov (NCT01272219 et al.)<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Saxenda Liraglutide Saxenda is a brand-name prescription medication containing\u00a0liraglutide\u00a0(3 mg\/3 mL solution for subcutaneous injection). It&#8217;s a GLP-1 receptor agonist (glucagon-like peptide-1), mimicking a hormone&#8230;<\/p>","protected":false},"featured_media":4594,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"etheme_brands":[],"product_brand":[],"product_cat":[56],"product_tag":[134],"class_list":["post-4556","product","type-product","status-publish","has-post-thumbnail","product_cat-weight-loss","product_tag-saxenda-liraglutide","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product\/4556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/comments?post=4556"}],"version-history":[{"count":1,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product\/4556\/revisions"}],"predecessor-version":[{"id":4595,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product\/4556\/revisions\/4595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/media\/4594"}],"wp:attachment":[{"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/media?parent=4556"}],"wp:term":[{"taxonomy":"brand","embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/etheme_brands?post=4556"},{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product_brand?post=4556"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product_cat?post=4556"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/peptoscience.com\/es\/wp-json\/wp\/v2\/product_tag?post=4556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}